Antiviral activity of ciclesonide acetal derivatives blocking SARS-CoV-2 RNA replication

E-resources

Peer reviewed Open access

Antiviral activity of ciclesonide acetal derivatives blocking SARS-CoV-2 RNA replication

Tsuji, Genichiro; Nakajima, Shogo; Watashi, Koichi; Torii, Shiho; Suzuki, Rigel; Fukuhara, Takasuke; Ohoka, Nobumichi; Inoue, Takao; Demizu, Yosuke

Journal of pharmacological sciences, 07/2022, Volume: 149, Issue: 3

Journal Article

Ciclesonide (Cic) is approved as an inhalant for asthma and was clinically tested as a candidate therapy for coronavirus disease 2019 (COVID-19). Its active metabolite Cic2 was recently reported to suppress genomic RNA replication of severe acute respiratory syndrome coronavirus 2. In this study, we designed and synthesized a set of ciclesonide-acetal (Cic-acetal) derivatives. Among designated compounds, some Cic-acetal derivatives with a linear alkyl chain exhibited strong viral copy-number reduction activities compared with Cic2. These compounds might serve as lead compounds for developing novel anti-COVID-19 agents.

Keep searching

Author

Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.

Year	Impact factor		Edition		Category		Classification
Year	JCR	SNIP	JCR	SNIP	JCR	SNIP	JCR	SNIP

Links to authors' personal bibliographies	Links to information on researchers in the SICRIS system

Source: Personal bibliographies and: SICRIS

Upload image

Shelf entry

Adding material to shelf was successful.

Adding material to shelf failed.

It was not necessary to add the material to the shelf.

Permalink

E-mail

Impact factor

Select the library membership card:

DRS, in which the journal is indexed

Citations

Theme